If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
This enzyme found in yeasts and humans converts D-ribosylnicotinate to nicotinate mononucleotide by transferring a phosphate group from the cofactor, adenosine triphosphate (ATP), which is converted to adenosine diphosphate (ADP). This is part of the biosynthetic pathway to nicotinamide adenine dinucleotide. An alternative substrate for the enzyme is nicotinamide riboside, similar to the enzyme ribosylnicotinamide kinase.
transcriptional bursting The intermittent nature of transcription and translation mechanisms. Both processes occur in "bursts" or "pulses", with periods of gene activity separated by irregular intervals.
== External links == Finding Aid to The Dr. Michael Somogyi Collection, 1912–1979 (bulk 1924–1970) at the Science History Institute (For full finding aid, click on 'Dr. Michael Somogyi Collection Finding Aid'.) Finding Aid to Photographs from the Dr. Michael Somogyi Collection, 1912–1971 (bulk 1950s) at the Science History Institute (For full finding aid, click on 'Dr. Michael Somogyi Collection Finding Aid'.)
== Paralogs == Escherichia coli (E. coli) expresses two different forms of shikimate dehydrogenase, AroE and YdiB. These two forms are paralogs of each other. The two forms of shikimate dehydrogenase have different primary sequences in different organisms but catalyze the same reactions. There is about 25% similarity between the sequences of AroE and YdiB, but their two structures have similar structures with similar folds. YdiB can utilize NAD or NADP as a cofactor and also reacts with quinic acid. They both have high affinity of their ligands as shown by their similar enzyme (Km) values. Both forms of the enzyme are independently regulated.
Humps which mostly contain fat can shrink or disappear depending on conditions. When camels are born, the humps are small and may appear deflated, but will grow as the calf begins to eat solid food. Adult camels that suffer extreme stress, such as heavy parasite loads, may lose their humps due to depletion of fat reserves. Captive plains bison may arch their backs (or "hump up") as a stress response, especially if in close confinement, which can create the illusion that their actual hump is much lower at the shoulders. Humps can take different forms, even between closely related species. The dromedary camel has only one hump, while the bactrian camel has two. This may be due to differences in fat metabolism rates, as the two-humped bactrian evolved lipid metabolism more rapidly. Yaks have humps comparable to the breastbone of a bird, while zebus have lump-like humps; when the two are crossbred, the yak's hump gene is dominant over the zebu's. In some cattle breeds, like the Drakensberger and Nguni, the hump is sexually dimorphic, with only bulls having one. In other breeds, like the Boran, both sexes have a hump, but it is larger in the male.
Sources: en.wikipedia.org
=== Drug effects === Understanding how drugs affect neurotransmitters constitutes a major area of research in neuroscience. Many neuroscientists believe that these studies can improve understanding of the neural circuits involved in neurological and psychiatric disorders, and may contribute to the development of more effective treatments, as well as strategies for prevention and, potentially, cures. Drugs can influence behavior by altering neurotransmitter activity in the nervous system. Some drugs affect neurotransmitter synthesis by altering the activity of the enzymes involved in their production. When neurotransmitter synthesis is inhibited, the amount of neurotransmitter available for release decreases, thus reducing neurotransmitter activity. Other drugs act by stimulating or blocking the release of specific neurotransmitters. Some drugs also interfere with neurotransmitter storage by causing synaptic vesicles to leak, thereby reducing the amount of neurotransmitter released into the synapse. Drugs that prevent a neurotransmitter from binding to its receptor are known as receptor antagonists. For example, antipsychotic drugs such as haloperidol, chlorpromazine, and clozapine act primarily as antagonists at dopamine receptors in the brain. In contrast, receptor agonists bind to receptors and mimic the effects of endogenous neurotransmitters. An example is morphine, an opioid receptor agonist that mimics the actions of endogenous opioid peptides such as β-endorphin to relieve pain.
Turin is the Italian city where film chromatography was first established. As such, it forms the birthplace of Italian cinema. Because of its historic, geographical and cultural proximity to France, Italian filmmakers were naturally influenced by French cinema and the Lumière brothers. The first Italian cinema screening occurred in Turin in March 1896. In November 1896, Italian filmmakers performed the first cinema screening of a film before a fee-paying audience. By the start of the 20th century (especially after 1907), a number of the first Italian films were aired in Turin. Examples include Giovanni Pastrone Cabiria, in 1914, one of the first blockbusters in history. The Turin-based company Ambrosio Film, established in 1906 by Arturo Ambrosio, was one of the leading forces in Italian cinema and boosted the importance of the city as a filmmaking destination. The company, noted in particular for its historical epics, produced a large number of films until it was dissolved in 1924. During the 1920s and 30s, Turin hosted a number of film productions and major film studios (film houses), such as the Itala film, Aquila and Fert Studios. Today their heritage is in the modern Lumiq Studios and Virtual Reality Multi Media Spa. Turin's prominence in Italian film continued until 1937, the year Cinecittà was inaugurated in Rome. After World War II, the cinematic scene in Turin continued to thrive. 1956 saw the opening of the National Museum of Cinema, first housed in the Palazzo Chiablese and then, from 2000, in the imposing headquarters of the Mole Antonelliana.
=== 10 January === Ukrainian steel production was reduced by about 70% in 2022 as a result of the conflict. US and Ukrainian officials stated that Russian artillery fire had declined nearly 75% in some places. The UK said most of Soledar was under Russian control, whereas Wagner claimed all.
=== Allergy === Molecular diagnostics is increasingly used in allergology, especially for food and respiratory allergy. Conventional diagnosis is based on clinical history, skin-prick testing and measurement of serum allergen-specific IgE to whole allergen extracts. Molecular-based allergy diagnostics, also called component-resolved diagnostics, measures IgE to individual allergen molecules rather than only to extracts. This can help distinguish genuine sensitization from cross-reactivity, refine assessment of clinical risk in some allergies, and support decisions about allergen immunotherapy. Multiplex platforms, such as Allergy Explorer (ALEX), can test IgE reactivity to many allergen extracts and molecular components in a single assay. Precision allergy molecular diagnosis (PAMD®) is a broader diagnostic approach using molecular IgE profiles to guide prognosis, risk assessment and personalized management, although results must be interpreted together with the patient’s clinical history.
== Activating reagent == NHS is commonly found in organic chemistry or biochemistry where it is used as an activating reagent for carboxylic acids. Activated acids (carboxylates) can react with amines to form amides for example, whereas a normal carboxylic acid would just form a salt with an amine.
Sources: en.wikipedia.org
==== Structure ==== There are three structural zones in articular cartilage including a superficial tangential zone, a middle transitional zone and a deep zone. In the tangential zone, collagen fibers are aligned parallel to the surface and become gradually randomly aligned while moving into the deep zone. Collagen fibers in the superficial zone are aligned parallel to the surface in order to restrict shear stresses. Similarly, collagen fibers are aligned perpendicular to the surface in the deep zone in order to restrict compressive forces. Between bone and the deep zone lies calcified cartilage. Cell arrangement also varies between the zones, in deeper zones chondrocytes are stacked into columns while in the superficial zones they are arranged randomly. In the superficial regions the cells are also more elongated, while in deeper zones they are more spherical in nature.
Animal hair (wool or hairs): Fiber or wool taken from animals or hairy mammals. e.g. sheep's wool, goat hair (cashmere, mohair), alpaca hair, horse hair, etc. Silk fiber: Fiber secreted by glands (often located near the mouth) of insects during the preparation of cocoons.
=== Brittle-cornea syndrome === Brittle-cornea syndrome (BCS) is characterized by the progressive thinning of the cornea, early-onset progressive keratoglobus or keratoconus, nearsightedness, hearing loss, and blue sclerae. Classic symptoms, such as hypermobile joints and hyperelastic skin, are also often seen. It has two types. Type 1 occurs due to variations in the ZNF469 gene. Type 2 is due to variations in the PRDM5 gene.
In broad terms, spent nuclear fuel has three main components. The first consists of fission products, the leftover fragments of fuel atoms after they have been split to release energy. Fission products come in dozens of elements and hundreds of isotopes, all of them lighter than uranium. The second main component of spent fuel is transuranics (atoms heavier than uranium), which are generated from uranium or heavier atoms in the fuel when they absorb neutrons but do not undergo fission. The actinide series on the periodic table runs from actinium to lawrencium and includes uranium as well as transuranic elements. The third and largest component is the remaining uranium which is around 98.25% uranium-238, 1.1% uranium-235, and 0.65% uranium-236. The U-236 comes from the non-fission capture reaction where U-235 absorbs a neutron but releases only a high energy gamma ray instead of undergoing fission. The physical behavior of the fission products is markedly different from that of the actinides. In particular, fission products do not undergo fission and therefore cannot be used as nuclear fuel. Indeed, because fission products are often neutron poisons (absorbing neutrons that could be used to sustain a chain reaction), fission products are viewed as nuclear 'ashes' left over from consuming fissile materials. Furthermore, only seven long-lived fission product isotopes have half-lives longer than a hundred years, which makes their geological storage or disposal less problematic than for transuranic materials.
On February 6, 2017, Duterte, citing continued attacks by the NPA on the military, formally terminated peace negotiations with the CPP-NPA-NDF, designated them as a terrorist organization and ordered the arrest of all NDF negotiators. Through an executive order he issued in December 2018, Duterte established the National Task Force to End Local Communist Armed Conflict (NTF-ELCAC), an inter-agency body that involved a whole-of-nation approach—from the national to local level— in addressing the root causes of communism. The NTF-ELCAC worked in close coordination with the military and focused on developing far-flung localities infiltrated by the NPA. Duterte also granted amnesty to former communist rebels and launched reintegration programs to support them and their families. Ultimately, in March 2019, he permanently terminated peace negotiations with the CPP-NPA-NDF, facilitating localized peace talks with the rebels. Duterte left office with the number of NPA guerrilla fronts in the country reduced from 89 to 23, and about 20,579 communist rebels reportedly surrendered from 2016 to 2021. Despite its success in reducing communist insurgency in the country, Duterte's administration was marred by numerous allegations of red-tagging, notably the left-leaning Makabayan Bloc; Duterte and the military dismissed the red-tagging accusations and argued the government was merely "identifying" them as communist fronts.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.